Company: MDCXW
Filing Date: 2025-08-12
Form Type: 424B3
Source: 0001062993-25-014087
Chunk: 28

Company: Medicus Pharma Ltd.
Filing Date: 2025-08-12
Form: 424B3
Chunk 28
---
 |   716,422 |     |     8,378 |   |     |                 1,264,698 |     |   894,232 |     |   370,466 |   |
| Business development and investor relations               |     |                     615,296 |     |   152,444 |     |   462,852 |   |     |                 1,080,240 |     |   229,530 |     |   850,710 |   |
|                                                           |     |                   4,576,524 |     | 2,276,676 |     | 2,299,848 |   |     |                 7,696,584 |     | 3,662,657 |     | 4,033,927 |   |

18 General and administrative General and administrative expenses for the three and six months ended June 30, 2025 and 2024 are comprised of: Professional fees increased by $1,323,519 and $2,245,695 for the three and six months ended June 30, 2025, compared to the equivalent period in the prior year. The increase was primarily due to increases in legal and accounting fees related to the Company's operations, as well as financing and transactional activities. Professional fees include fees incurred for legal and accounting services that fluctuate from period to period based on the nature of the transactions the Company undertakes. The primary reason for the increase is due to increased regulatory requirements following the Company's initial public offering, transition to U.S. domestic issuer status, multiple financing transactions and the Antev acquisition. Consulting fees decreased by $100,110 and $270,978 for the three and six months ended June 30, 2025, compared to the equivalent period in the prior year. Consulting fees include fees paid to individuals and professional firms who provide advisory services to the Company and fluctuate from period to period based on the nature of the transactions the Company undertakes. The primary reason for the decrease is due to decreased business activity in the current year compared to the prior year when the Company was focused on completing the initial public offering. Salaries, wages and benefits increased by $605,209 and $838,034 for the three and six months ended June 30, 2025, compared to the equivalent period in the prior year. The increase was primarily due to an increase in headcount from the previous year. General office, insurance and administration expenditures increased by $